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Abstract 
Background: The mechanisms by which vaccinia virus (VACV) interacts with the innate immune components are 
complex and involve different mechanisms. iNOS-mediated NO production by myeloid cells is one of the central anti-
viral mechanisms and this study aims to investigate specifically whether iNOS-mediated NO production by myeloid 
cells, is involved in tumor eradication following the virus treatment.
Methods: Human colon adenocarcinoma (HCT-116) xenograft tumors were infected by VACV. Infiltration of iNOS+ 
myeloid cell population into the tumor, and virus titer was monitored following the treatment. Single-cell suspen-
sions were stained for qualitative and quantitative flow analysis. The effect of different myeloid cell subsets on tumor 
growth and colonization were investigated by depletion studies. Finally, in vitro culture experiments were carried out 
to study NO production and tumor cell killing. Student’s t test was used for comparison between groups in all of the 
experiments.
Results: Infection of human colon adenocarcinoma (HCT-116) xenograft tumors by VACV has led to recruitment of 
many CD11b+ ly6G+ myeloid-derived suppressor cells (MDSCs), with enhanced iNOS expression in the tumors, and 
to an increased intratumoral virus titer between days 7 and 10 post-VACV therapy. In parallel, both single and multiple 
rounds of iNOS-producing cell depletions caused very rapid tumor growth within the same period after virus injec-
tion, indicating that VACV-induced iNOS+ MDSCs could be an important antitumor effector component. A continuous 
blockade of iNOS by its specific inhibitor, L-NIL, showed similar tumor growth enhancement 7–10 days post-infection. 
Finally, spleen-derived iNOS+ MDSCs isolated from virus-injected tumor bearing mice produced higher amounts of 
NO and effectively killed HCT-116 cells in in vitro transwell experiments.
Conclusions: We initially hypothesized that NO could be one of the factors that limits active spreading of the virus in 
the cancerous tissue. In contrast to our initial hypothesis, we observed that PMN-MDSCs were the main producer of 
NO through iNOS and NO provided a beneficial antitumor effect, The results strongly support an important novel role 
for VACV infection in the tumor microenvironment. VACV convert tumor-promoting MDSCs into tumor-killing cells by 
inducing higher NO production.
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Background
The mechanisms by which vaccinia virus (VACV) inter-
acts with the innate immune components may play 
a decisive role in its antitumor activity by tilting the 
immune response from viral clearance to tumor elimina-
tion. The inherent ability to rapidly replicate in, and lyse 
human tumor cells in comparison with other viruses as 
well as its large foreign gene-carrying capacity make 
VACV a leading candidate for the use in cancer therapy 
[1]. Until now, preclinical and clinical studies have dem-
onstrated that various VACVs have a broad spectrum of 
anticancer activity and good safety [2]. Tumor-targeting 
mechanisms of VACV include virus-mediated direct 
oncolysis, antivascular effects and induction of antitumor 
immune responses [3–5]. The latter mechanism of action 
might be essential in the elimination of tumor cells which 
are able to escape virus infection [6]. The three critical 
stages to ensure the effectiveness of any oncolytic virus 
therapy include: efficient virus targeting to tumor sites, 
fast and continuous virus replication in tumor cells, and 
resistance to the host antiviral immunity. Virus elimina-
tion by the host immune system is a major obstacle to 
the oncolytic virus therapy. An important question that 
remains to be answered is whether the host immune sys-
tem, adept at controlling viral infections, would also have 
an impact on the tumor.
The tumor microenvironment presents a niche, which 
supports the proliferation of malignant cells while pro-
moting the evasion of immune surveillance [7]. The 
recruitment of regulatory/suppressor immune cells like 
regulatory T cells, and myeloid-derived suppressor cells 
(MDSCs) ultimately enhances the pro-tumorigenic and 
suppressive nature of the microenvironment. MDSCs, 
which are induced by tumor-derived inflammatory 
factors, are a heterogeneous population of immature 
myeloid cells. They constitute a major part of the tumor-
infiltrating immune cells and play a central role in the 
regulation of the immune system [8]. In mice, they are 
characterized by the expression of CD11b and Gr-1. 
Anti-Gr-1 antibody, which binds to the myeloid differ-
entiation marker Gr-1, recognizes two epitopes, Ly6G 
and Ly6C. The classification made based on these mark-
ers initially revealed two main subsets of MDSC. The 
CD11b+ Ly6G+ Ly6Clo (PMN-) MDSC subset displays a 
granulocytic, polymorphonuclear phenotype, while the 
CD11b+ Ly6G− Ly6Chi subset exhibits a mononuclear 
phenotype (MO-) [9]. Lately, MDSCs have been catego-
rized into other different subsets [10]. Extensive stud-
ies have shown that MDSCs accumulate at tumor sites, 
suppress the antitumor immune response and promote 
tumor progression [11]. MDSCs use a variety of mecha-
nisms depending on different immune-regulators such as 
inducible nitric oxide synthase (iNOS), arginase, reactive 
oxygen species (ROS), and TGF-β. Among them, iNOS 
is expressed in high amounts and can act as a powerful 
modulator in different cancer-related events including 
apoptosis, angiogenesis, cell cycle, invasion, and metas-
tasis due to its substantial NO production [12]. Although 
the role of NO in mediating immune system such as 
inhibiting T cell proliferation or suppressing their func-
tion is very well documented, its effect on tumor cells 
remains controversial; In contrast to tumoricidal effects, 
NO has also been reported to have tumor promoting 
effects [13, 14]. The concentration and timing of the NO 
accumulation has been implicated in its dichotomous 
effects [15]. Therefore, understanding the role of iNOS+ 
cells in any anticancer approach will help in improving 
cancer treatment strategies.
The interaction of oncolytic viruses with myeloid 
cell components of the innate immune system has 
only recently become an important research endeavor. 
Recent reports have demonstrated the important role 
of myeloid cells in virus delivery and oncolytic therapy 
when macrophages or MDSCs were used as transport 
vehicles [16, 17]. Furthermore, MDSCs have an effect 
on the function of natural killer (NK) cells, when onco-
lytic viruses are introduced [18–20]. Lately, it has been 
proposed that VACV can act as an immunomodula-
tor, triggering an inflammation that can vanquish tumor 
driven protective mechanisms [4–21]. Virus infection 
at the tumor site leads to cell death, the release of dan-
ger signals, tumor antigens and inflammatory cytokines, 
which can overcome an established immunosuppressive 
microenvironment, subsequently initiating antitumor 
immune responses. We recently reported that coloniza-
tion of human colorectal cancer xenografts with the onc-
olytic VACV strain GLV-1h68 in nude mice, is followed 
by significant upregulation of murine proinflammatory 
cytokines and chemokines such as interferon-gamma 
(IFNγ), IFNγ-induced protein 10 (IP-10), monocyte 
chemoattractant protein (MCP)-1/3/5, macrophage 
inflammatory protein 1 (MIP-1), regulated on activation 
normal T cell expressed and secreted (RANTES), IL-6, 
IL-1b and tumor necrosis factors (TNF-α), as well as 
infiltration of F4/80low CXCR4+ myeloid cells [22]. This 
finding is in accordance with previous reports of differ-
ent tumor models [3, 23]. While virus-mediated inflam-
mation may lead to antitumor immunity, this response 
might also target viral vectors, limiting their therapeutic 
efficacy. One of the key elements of the antiviral response 
is iNOS, which is expressed by myeloid cells. iNOS-pro-
ducing M1 macrophages have been particularly shown 
to mediate the innate immune defense against viruses in 
infection models [24, 25]. However, how iNOS+ MDSCs 
could modulate the antitumor immune response during 
an infection of tumor tissue remains largely unknown. 
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Mechanistic studies exploiting the interaction of the host 
immune system with the oncolytic viruses are vital in 
understanding the therapeutic potential of VACV. Herein 
we report an extensive accumulation of iNOS+ MDSCs at 
VACV-infected tumor sites. In vivo depletion of this cell 
subset or blocking its function promoted tumor growth 
demonstrating the iNOS+ MDSCs’ potential therapeutic 
benefits. We further confirmed that a higher amount of 
NO production was responsible for synergistic tumor cell 
killing by VACV and MDSCs.
Methods
Cell culture, mice, tumor induction
Human colon carcinoma cells HCT-116 and African 
green monkey fibroblasts (CV-1) cells were cultured 
as described before [22]. Five- to six-week old male 
Hsd:athymic Nude-Foxn1nu mice (Harlan, Indianapolis, 
IN) were implanted subcutaneously (s.c.) with 5  ×  106 
HCT-116 cells (in 100  μL PBS) into the right hind leg. 
Tumors were allowed to reach a size of 250–350  mm3 
before treatment. All studies were approved by the Insti-
tutional Animal Care and Use Committee of Explora 
Biolabs (San Diego Science Center, protocol number 
EB11-025,CA).
Virus and reagents
LIVP 1.1.1 is a less virulent wild-type isolate of a strongly 
replicating LIVP strain as described before [26]. Tur-
boFP635 (aka Katushka) is a far-red fluorescent protein 
from sea anemone Entacmaea quadricolor [27]. For the 
generation of the GLV-2b372 from LIVP 1.1.1, the cDNA 
encoding for Katushka was PCR-amplified using the 
plasmid FUKW (kindly provided by Dr. Marco J. Her-
old, University of Würzburg, Würzburg, Germany) as a 
template with primers FUKW-5 (5′-GTCGACCACC 
ATGGTGGGTGAGGATAGCGTGC-3′) and FUKW-3 
(5′-TTAATTAATCAGCTGTGCCCCAGTTTGC-3′). 
The PCR product was gel-purified and cloned into the 
pCRII-Blunt-TOPO® vector (Life Technologies, Carlsbad, 
CA) and then released by enzymatic PacI/SalI (New Eng-
land Biolabs, Ipswich, MA) digestion. Subsequently, the 
cDNA fragment was subcloned into the vaccinia trans-
fer vector for the J2R (TK) locus, placing TurboFP635 
under control of the vaccinia synthetic early/late (SEL) 
promoter. The resulting plasmid construct pTK-SEL-
TurboFP635 was sequence confirmed and used for the 
construction of GLV-2b372 using guanine phosphoribo-
syltransferase selection [28]. LIVP 1.1.1, or GLV-2b372, 
GLV-1h68 were administered systemically to HCT-116 
tumor-bearing animals by retro-orbital (r.o.) injection 
of 2  ×  106 plaque-forming units (PFU) in 100  μL PBS 
on day 0. Control mice were injected with 100  μL PBS. 
For monocytic or granulocytic cells depletion, animals 
received single vs. continuous (twice per week) intraperi-
toneal (i.p.) injections of clodronate liposomes (2  mg) 
(Encapsula NanoSciences, Brentwood, TN) or 1A8 rat 
mAb (1 mg) (BioXCell, West Lebanon, NH), respectively. 
For inhibition of iNOS activity, N6-(1-iminoethyl)-l-
lysine dihydrochloride (L-NIL) was injected i.p. initially 
at a dose of 0.2 mg/100 μL PBS followed by 0.1 mg every 
other day. Nanoparticles were formulated as previously 
described with minor modifications [29]. In brief, 30 mg 
PLGA and 2 mg of LPS (Sigma, St. Louis, MS) in 1 mL of 
chloroform was emulsified in 6 mL of 2% PVA to form an 
oil-in-water emulsion. The emulsification was carried out 
using a micro-tip probe ultrasonic sonicator set at 55 W 
of energy output (XL 2015 Sonicator® ultrasonic proces-
sor; Misonix, Inc, Farmingdale, NY) for 2 min over an ice 
bath. The emulsion was stirred overnight on a magnetic 
stir plate to allow evaporation of chloroform and forma-
tion of PLGA-NPs. PLGA-NPs were recovered by ultra-
centrifugation at 30,000 rpm for 30 min at 4 °C (Beckman 
OptimaTM LE-80K, Beckman Instruments, Pasadena, 
CA), washed twice with sterile nano water to remove 
PVA and then lyophilized for 48  h (VirTis Company, 
Freeze Dryer, Stone Ridge, NY). An analysis of the LPS 
nanoparticles was made using the EndoZyme Kit (Hyglos 
GmbH, Germany), using manufacturer’s protocol. The 
concentration was 7.3 μg of LPS/mL of nanoparticles.
Preparation of single cell suspensions, enrichment 
and fluorescence‑activated cell sorting (FACS)
Mice were followed for a period of up to 21  days post-
infection (d.p.i.) and were sacrificed at specific time 
points (1, 3, 7, 14, 21 d.p.i). Single-cell suspensions from 
tumors and spleen were prepared essentially by enzy-
matic digestion as previously described [2]. Flow cyto-
metric analysis was performed on a FACSCanto flow 
cytometer (BD Pharmingen, San Jose, CA) at VA hospi-
tal Flow Cytometry Core facility using established pro-
tocols. Flow analysis, gating strategy and determination 
of the absolute number regarding the cell population in 
interest were explained in detail in our previous publica-
tion [30]. Fluorochrome-conjugated anti-mouse mono-
clonal Antibodies (mAbs) to iNOS (6/iNOS/NOS type 
II), CD11b (M1/70), Ly6G (1A8), CD45 (30-F11), and all 
isotype controls were purchased from BD Pharmingen. 
F4/80 (BM8) was obtained from eBioscience, San Diego, 
CA. Intracellular iNOS staining was as described previ-
ously [13].
Vaccinia viral titers
Tumors were excised and placed in 500  μL of PBS sup-
plemented with Complete Protease Inhibitor Cocktail 
(Roche Diagnostics, Indianapolis, IN). Samples were then 
homogenized using a MagNA Lyser (Roche Diagnostics) 
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at a speed of 5000  rpm for 30  s. Following three subse-
quent freeze–thaw cycles (−80  °C/37  °C water bath), 
tumor supernatants were collected by centrifugation 
(600g, 5 min, RT). Viral titers in tumor supernatants were 
measured by standard plaque assay on 24-well plates of 
confluent CV-1 cells, with all samples assessed in dupli-
cate, as described previously [22].
In vivo fluorescence imaging of TurboFP635
In vivo fluorescence imaging and analysis was performed 
using a Carestream animal imager (excitation, 590  nm; 
emission, 670 nm) using the Molecular Imaging Second 
Edition software (Carestream Health, Rochester, NY). 
Background fluorescence was subtracted and data were 
presented as mean relative fluorescent units (RFU) per 
tumor area.
In vitro culture experiments
To purify iNOS+ cells, single-cell suspensions from 
spleen were magnetically labeled with anti-Ly-6G micro-
Beads according to the manufacturer instructions and 
then the cell suspension was loaded onto autoMACS in 
order to enrich Ly-6G+ cells (Miltenyi Biotec, Cologne, 
Germany). The purity of the total iNOS+ population was 
typically higher than 90%. Isolated and combined iNOS+ 
effector cells (from 3 to 4 mice per group) were placed 
into the upper chamber of 96-well Transwells (0.4  μm 
pore size membrane; Corning, NY) at different E:T 
ratios. The lower chamber of the Transwells contained 
5000 HCT-116 target cells plated overnight. Coculture 
was conducted in MLR media [DMEM plus 5% FBS with 
10 mM HEPES (pH 7.4), 1% sodium pyruvate, 1% peni-
cillin/streptomycin, 1% l-glutamine, 0.4% l-arginine HCl, 
1% folic acid/l-asparagine, and 0.2% 2-ME] supplemented 
with recombinant Murine IFN-γ (20  ng/mL, Peprotech, 
Rocky Hill, NJ) and the specific killing of target cells was 
tested by using Alamar Blue (Invitrogen, Waltham, MA) 
which is added at 10% of the sample volume followed by 
4–16  h incubation. Every 4  h the resulting Alamar blue 
fluorescence was read on SpectraMax M5 reader (Molec-
ular Devices, Sunnyvale, CA) with excitation at 540 nm 
and emission, 590 nm. The percentage of lysis was calcu-
lated using the formula; %Lysis = 100 × {[(AF of targets 
alone)] − [(AF of mix) − (AF of effectors alone)]}/{AF of 
targets alone} where AF is the mean fluorescence for the 
triplicate wells after the mean fluorescence of the wells 
containing medium alone was subtracted. To block NO 
production in some wells, L-NIL at a final concentration 
of 0.5  mM was added. In another experimental setup, 
Annexin V Apoptosis Detection Kit I was used for viabil-
ity staining according to the manufacturer instructions 
(BD Pharmingen) and culture supernatant was collected 
for NO measurement. Nitrite assay was performed as 
described before [30].
Statistical analysis
Student’s t test was used for comparison between groups 
in all of the experiments. In all analyses, p  ≤   0.05 was 
considered significant.
Results
Robust increase of tumor‑infiltrating iNOS+ myeloid cells 
during viral infection
We first monitored the tumor growth and the infiltration 
of iNOS+ myeloid cell population into HCT-116 tumors 
after treatment. Starting from day 10-post virus injection, 
tumor growth stopped in LIVP 1.1.1-treated animals and 
entered a steady-state phase followed by regression while 
control tumors continued to grow (Fig.  1a). In order to 
study the accumulation kinetics of iNOS+ subsets on day 
1, 3, 7, 14, and 21 following the treatment, single-cell sus-
pensions from spleen and primary tumors were stained 
for Ly6G, CD11b and F4/80 and iNOS. Homogeneously 
stained single population of CD11b+ly6G+F4/80low cell 
subset expressing iNOS was detected both in spleens and 
tumors (Fig. 1b). The phenotype of the tumor-infiltrating 
myeloid cells resembled PMN-MDSCs described previ-
ously by us and others [9, 30]. Since LPS is well known to 
induce iNOS expression [31], LPS-containing nanoparti-
cles, were used as a positive control in these experiments. 
The absolute number of intratumoral MDSC expressing 
iNOS increased rapidly within 24  h, and subsequently 
dropped in LPS-nanoparticle-treated alone (white and 
black-dotted bar) as well as LPS-nanoparticle  +  LIVP 
1.1.1 combination-treated groups (black bar). The accu-
mulation of PMN-MDSCs in a single dose LIVP 1.1.1 
injection group however was delayed until day 7 post-
treatment, followed by the most drastic change with 
an average of 72-fold increase between days 7 and 14 
(Fig.  1c). Combination treatment resulted in the same 
kinetics; although it is interesting to note that this group 
recruited the highest amount of intratumoral iNOS+ 
PMN-MDSCs on day 14, which correlated with slightly 
improved tumor regression. Furthermore, the difference 
in tumor size between the combination therapy group 
and control (PBS or LPS alone) groups reached a statis-
tically significant level on day 21 (p  <  0.0001). Analysis 
of the iNOS+ PMN-MDSCs infiltration kinetics in the 
spleen revealed that accumulation of these cells followed 
the same trend observed in the tumor. A statistically 
significant increase for their average absolute number 
among different groups was not detected before day 7. 
Thereafter iNOS+ PMN-MDSCs populated the spleen 
with a significant fourfold increase on day 14 (p = 0.02) 
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which did persist, but not significantly, until 21  days 
postinfection (dpi) in both of the virus-treated groups.
The lack of immunocompetent models for investigat-
ing therapies with our VACV constructs required us to 
establish xenograft tumor models in which tumor cells 
could support viral replication in spite of fully intact 
innate immunity. Like many other oncolytic viruses, vac-
cinia virus replication is considered to be species-spe-
cific and similarly, our VACV constructs replicate well 
in human tumors, with poor replication seen in most 
murine tumor cell lines. Nevertheless, the elevated level 
of Gr1+CD11b+ cell infiltration were observed in many 
other different models such as vesicular stomatitis virus 
(VSV) in melanoma and mesothelioma, Western Reserve 
strain VV (Vvdd) in AT-3, Reovirus in ovarian cancer 
pointing out these cells may play an important role in 
anti-VACV immune response [18, 32–34].
Tumor regression coincides with the accumulation 
of PMN‑MDSCs and enhanced iNOS expression
Next, we sought to determine whether the prevalence of 


























































































Fig. 1 Effect of VACV on tumor growth and post-therapy intratumoral PMN-MDSC kinetics. a Growth of HCT-116 tumors in LIVP 1.1.1 and control-
treated mice. Tumor-bearing nude mice were treated with a single injection of LIVP 1.1.1 or LPS-nanoparticles or combination of both or PBS alone 
(uninfected). Tumor size was measured twice a week. Data shown are representative of two independent experiments with similar results. Error bars 
indicate SD (n = 3–5 mice/group). b Pre-treatment flow cytometry analysis of PMN-MDSCs in both tumor and spleen. A major iNOS+ cell subset 
with a phenotype of CD11b+ly6G+F4/80low was detected in single cell suspensions from both tumor and spleen. FACS plots are shown with the 
population of interest (PMN-MDSCs) in bold circles. c, d Accumulation kinetics of PMN-MDSC upon VACV treatment. The absolute numbers of PMN-
MDSCs were determined by flow cytometry. Results are expressed as the average number of cells per gram of tissue and were obtained from three 
separate experiments with 3–5 mice. Error bars represent mean and SD. The differences between the VACV alone treated group (dark gray bar) and 
untreated controls (light gray bar) were significant for day 14 (tumor; p = 0.014 and spleen; p = 0.02) and for day 21 (tumor; p = 0.006). Black bars 
and light gray bars represent LIVP 1.1.1 + LPS-nanoparticles combination and untreated controls respectively
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with tumor growth and/or controlled viral load. Ini-
tially, we hypothesized that excessive iNOS+-cell migra-
tion into the tumor in response to viral infection would 
cause viral clearance. Earlier studies reported that nitric 
oxide production is a key effector factor in antiviral 
activities against VACV [35, 36]. Recent reports how-
ever suggested the opposite and indicated that NO is 
not essential for the control of VACV’s replication or 
dissemination [37, 38]. To determine the virus infec-
tion kinetic in tumors, mice treated with LIVP 1.1.1 and 
1h68 were sacrificed on 3, 7, 14 and 21 dpi and tumor tis-
sues were homogenized. Figure 2a shows the results of a 
viral titer analysis as pfu/gram of tumor. Three days after 
LIVP 1.1.1 injection, 4.6 × 105 ± 1.4 × 105 viral pfu were 
detected in the tumor (Fig. 2a). The exponential increase 
in LIVP 1.1.1 titer reached its maximum at a two-log 
fold level on day 14 postinfection. Consistent with our 
previous data [22], viral colonization pattern for 1h68 
followed identical trend as of LIVP 1.1.1 except that a 
significantly lower titer compared to primary LIVP 1.1.1 
tumors was observed at all-time points. As the tumor 
growth started to decrease between days 7 and 14, VACV 
particles along with the actual number of iNOS+ cells in 
the tumor started to increase indicating an inverse rela-
tionship between the average tumor volume (ATV) and 
iNOS+ cells induced by the virus (Fig. 2b). Moreover, the 
gradual increase in the viral replication and infection of 
the tumor induced an increase in the expression of iNOS 
as detected by mean fluorescence Intensity (MFI) starting 
from day 7. A higher iNOS expression by PMN-MDSC 
was observed in the tumor (47.4 × 103 ± 6.9 × 103) com-
pared to the level in the spleen (38.9 × 103 ± 1.8 × 103) 
as shown in the histogram (Fig. 2c). The following figure, 



































































Fig. 2 Result of iNOS expression on virus titer and tumor volume. a HCT-116 tumors were harvested 3, 7, 14 and 21 dpi and infectious viral particles 
were quantitated on CV-1 (n = 3–5 mice/time point/experiment). The bar graph shows the mean virus titer as PFU per gram of tumor for both LIVP 
1.1.1 and GLV-1h68 as test versus control virus (GLV-1h68 is a recombinant isolate from the VACV LIVP strain, as described previously [41]), respec-
tively. b An inverse relationship between the average tumor volume and the number of iNOS+ cells induced by LIVP 1.1.1. The plot represents the 
infiltration kinetics of iNOS+ cells (solid line) over change in tumor growth (bars) on days 7, 14 and 21. c iNOS expression was assessed as relative MFI 
using flow cytometry. Histogram shows relative MFI on gated iNOS+ PMN cells isolated from the tumor and spleen on day 7. d The change of iNOS 
MFI over time. All of the treatment groups have a significant difference from the control except for the day 21; day 7 tumor; p = 0.0174 and spleen; 
p = 0.0035 and day 14 tumor; p = 0.0079 and spleen; p = 0.0052). Each time point was repeated at least two times
Page 7 of 12Kilinc et al. J Transl Med  (2016) 14:340 
of MFI level stayed constant till day 14 but leveled off on 
day 21. Overall, our results suggested that NO might play 
an important role in the VACV-induced pathogenesis 
by enhancing the suppression of tumor growth without 
affecting the viral load.
Depletion of different myeloid cell subsets causes diverse 
effects on intratumoral VACV colonization and tumor 
growth
To evaluate the significance of Ly6G+ iNOS+ MDSCs 
accumulation in the tumor following VACV infection, we 
next carried out depletion studies. We tested both anti-
Ly6G antibody (mAb 1A8) and clodronate encapsulated 
liposomes (Clodrosome) to particularly deplete Ly6Ghigh 
iNOS+-MDSCs. A single injection of 1 mg of 1A8 2 days 
prior to virus treatment resulted in more than 95% deple-
tion of iNOS+ cells in both spleen and the tumor as com-
pared to isotype control treated samples and detected by 
their total cell number counts. Mice administered with 
Clodrosome (2 mg) showed a substantial reduction in the 
number of both the splenic and intratumoral F4/80+ cells 
as compared to empty liposomes, whereas the reduction 
of iNOS+ cell number in the spleen and tumors remained 
at the level of 46 and 32%, respectively. Figure 3a shows a 
representative dot plot of mouse administered with 1A8 
or Clodrosome as compared to control depletions on the 
day of infection (Fig. 3a). We concluded that Clodrosome 
depleted primarily monocytic cells (macrophages and/or 
MO-MDSCs) and 1A8 depleted Ly6Ghigh iNOS+ PMN-
MDSCs. The effect of depletion (a single versus multi-
ple injections) on tumor growth in different groups was 
shown in Fig.  3b. We observed an initial tumor growth 
until day 7 in all of the treated groups although for the 
following next 3 days the growth patterns showed a varia-
tion with respect to different depletion regiments. While 
the tumors grew with a 1.6-fold increase in size in both 
of ly6G+ depletion groups (single or multiple), deple-
tion of F4/80+ cells caused tumor regression. Although it 
was not significant, continuous depletion of ly6G+ cells 
further enhanced the growth until day 17. After day 17, 
an overall tumor regression was observed in all of the 
groups. These results suggested a role for iNOS+ cells 
as being part of an important effector mechanism dur-
ing oncolysis, especially between days 7 and 10  p.i. In 
the next set of experiments, we used a selective iNOS 
inhibitor, L-NIL, to further confirm the involvement of 
PMN-MDSCs in tumor regression. Blocking of iNOS by 
its specific inhibitor showed an identical tumor growth 
induction trend between day 7 and 10 post infection 
as seen in the depletion experiments (Fig.  3c). Having 
established that neutrophilic iNOS+-MDSCs are par-
ticipating in tumor regression, we next sought to con-
firm virus infection in the tumor without sacrificing the 
animals. Both LIVP 1.1.1 and its red-colored derivative 
GLV-2b372 were both similarly effective and tumors 
grew at an identical rate in HCT-116 and other tested 
models (data not shown). Fluorescence images obtained 
on day 3, 7 and 14 post-infection established a different 
kinetics of virus infection between the depletion groups 
(Fig. 3d). Clodrosome depletion of F4/80+, but not 1A8 
depletion of iNOS+ cells, resulted in a massive infec-
tion of the tumor as early as 3 days p.i. as detected by the 
fluorescence light intensity of VACV-infected tumors. 
This rapid and extensive infection by VACV resulted in a 
better tumor regression in F4/80+ depleted-group com-
pared to the iNOS+ depleted-group (Fig.  3b). The sum-
mary graph in Fig.  3e shows the relative fluorescence 
light intensity normalized to tumor volume. The deple-
tion of F4/80+ cells every 3 days caused the most signifi-
cant VACV replication and subsequent tumor regression 
starting from day 10. The data demonstrate that the cells 
responsible for restricting the tumor infection efficiency 
are monocytic rather than neutrophilic in origin. Overall, 
these results suggest that different myeloid cell subsets 
play different roles in the induction of antiviral immu-
nity and antitumor immunity, and that these roles are not 
mutually exclusive.
iNOS+ MDSCs have a cytotoxic effect on tumor cells due 
to NO production
Although the difference between iNOS+ PMN-MDSCs 
depleted groups and undepleted groups or L-NIL treated 
group and untreated groups were not statistically differ-
ent, we observed a trend that suggested a potential thera-
peutic benefit by MDSCs’ high iNOS activity on tumor 
regression. To verify whether PMN-MDSCs cells were 
converted to tumor-killer cells in VACV treated mice, 
these cells were tested for in vitro cytotoxicity on tumor 
cells and NO production. Ly6G+ cells were purified from 
the spleen of tumor bearing mice on day 10  p.i. using 
Miltenyi anti-Ly-6G MicroBead kit and were co-cultured 
with HCT-116 cells in transwell system at various E:T 
ratios. The iNOS+ cell-mediated killing of target cells was 
significantly increased in the GLV-2b372-treated mice, 
but not in the control mice (Fig. 4a), in a dose-dependent 
manner. Although 1:1 E:T ratio did not affect the cytotox-
icity, there was 1.76-fold increase in the cytotoxic activ-
ity of iNOS+-MDSC at a 5:1 E:T ratio. Cytotoxicity was 
due to NO secretion into culture media since addition of 
L-NIL reversed the killing of HCT-116 as it was detected 
by Alamar Blue CTL assay. To confirm that NO has an 
apoptotic effect on tumor cells, Annexin V staining was 
performed on HCT-116 cells isolated from the lower 
Transwell chamber and analyzed by flow cytometry. As it 
is shown in Fig. 4b, tumor cells co-incubated with iNOS+ 
MDSCs isolated from the spleen of GLV-2b372-treated 
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mice had a higher apoptosis rate (39 ±  2.24%) as com-
pared to the tumor cells co-cultured with iNOS+-MDSCs 
isolated from control mice (27 ±  1.69%). The cytotoxic 
effect of iNOS expression was also overlapped with sig-
nificantly increased nitrite concentrations in the cul-
tures, indicative of high NO production as assessed in the 
supernatant (Fig. 4c).
Discussion
Recent advances in oncolytic immunotherapy suggest a 
significant role for this promising approach in the fast-
expanding immuno-oncology field. It is acknowledged 
that host immunity contributes significantly to the 
oncolytic virus mediated antitumor response [39]. The 
innate immune system is primarily responsible for the 
initial containment of a virus, the viral infection, replica-
tion, spread and also the promotion of the initiation of 
an adaptive immune response against the viral patho-
gen. Accumulating data indicate that antiviral immunity 
adversely affects the efficacy of oncolysis by prematurely 
eliminating oncolytic viruses [40]. Paradoxically, the 
same antiviral response may have antitumor activities. 
Hence, during the infection, one of the mechanisms, 
iNOS-derived NO production by mature macrophages, 
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Fig. 3 Targeting different myeloid cell subsets. a A representative FACS dot plot shows the results of depletion by mAb 1A8 or clodrosome. iNOS+ 
neutrophilic (Neu) and F4/80+ monocytic cells (Mac) were depleted to different extents 48 h. post-depletion. b, c Depletion or blocking of iNOS+ 
Neutrophilic cells showed a similar result on tumor growth between days 7 and 10 post-VACV infection. The effect of single or multiple-depletion 
of iNOS+ neutrophilic (Neu) versus F4/80+ monocytic cells (Mac) on tumor size in b was compared to the iNOS-blocking agent, L-NIL in c. d, e 
Monitoring of tumor growth by fluorescence imaging. Carestream imaging system performed visualization of viral tumor colonization and the 
signal intensity was quantified as mean RFU per tumor area. The results shown are from one of two independent experiments that produced similar 
results
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is being activated to support the innate host defense 
against viruses and any other pathogenic microorgan-
isms. We initially hypothesized that NO could be one of 
the factors that limits active spreading of the virus in the 
cancerous tissue. In contrast to our initial hypothesis, we 
observed that PMN-MDSCs were the main producer of 
NO through iNOS; NO provided a beneficial antitumor 
effect. We found that the recruitment of iNOS+-MDSCs 
at the VACV-infected tumor sites was significantly accel-
erated starting from 7  dpi. Despite the spike in their 
number and higher iNOS expression, virus titer was not 
reduced. The depletion of iNOS+-MDSCs as well as the 
administration of a selective iNOS inhibitor both induced 
tumor growth, implicating a role in tumor cell killing 
mechanism complementary to lysis by VACV. Finally, we 
showed that expression of iNOS was associated with a 
significant increase in NO production and tumor cell kill-
ing as demonstrated by in ex vivo experiments. This cell 
killing was transient and iNOS over expression returned 
to prior-infection levels between days 14–21. Whether 
this temporary effect can be further manipulated as an 
effective mechanism to control the tumor growth is 
currently unknown, but would be the subject of further 
studies.
GLV-1h68 is a recombinant isolate from the VACV 
LIVP strain, as described previously [41]. LIVP 1.1.1 
is a less attenuated clonal isolate of the LIVP strain and 
has been recently tested as a more potent alternative to 
Fig. 4 Functional change in iNOS+ MDSCs. a Total iNOS+ cells were harvested from the spleen of mice treated by VACV (10 d.p.i) (filled square) or 
untreated mice (open square). Isolated cells were mixed at the indicated ratios with HCT-116 target cells in a transwell system for 12 h. In addition, 
where indicated, 0.5 mM L-NIL was added to inhibit NO production. Cytotoxicity was measured by Alamar blue CTL assay and tumor killing was 
shown as % lysis. Experiments were performed in triplicate, n = 2. Error bars represent mean and SD. b In a separate experiment, HCT-116 cells 
isolated from the lower transwell chamber were analyzed by flow cytometry for apoptosis at the end of 12 h of culture period. The data is presented 
as % Annexin V+ cells. This is representative data out of two distinct experiments with similar results. c NO level was determined by nitrite measure-
ment in the media. The culture supernatant obtained at 12 h of incubation period was used for the determination of nitrite level
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GLV-1h68 for clinical trials [26]. We previously analyzed 
the effect of a single administration of GLV-1h68, cur-
rently in human clinical Phase I/II trials as GL-ONC1, 
on the growth of HCT-116 colorectal cancer xenografts 
in nude mice [22]. This study suggested an early role of 
myeloid cells in triggering antitumor immune activity, 
although the mechanisms remained to be characterized.
In the tumor, NO was shown to be both friend and foe 
[5, 14]. It is believed that by producing variable levels of 
NO, iNOS can orchestrate various functions in different 
microenvironments [15]. Although observations about 
NO production as a result of oncolytic viruses cancer 
therapy are occasionally reported, the effect of the VACV 
infection on iNOS production by immature myeloid 
cells and the role of NO with regard to tumor regression 
and virus survival in vivo have not been studied for this 
sole purpose before. Therefore, in this study, we focused 
mainly on the action mechanism of iNOS+-MDSC as 
a response to VACV therapy and investigated VACV 
induced-NO production and its effect on virus replica-
tion efficiency and tumor regression.
Antiviral effects of NO, produced from phagocytic cells 
such as neutrophils and macrophages are well known 
for some viruses, typically DNA viruses [24]. However, 
NO production does not necessarily correlate with viral 
clearance in the infected tumor, as our data suggested. 
NO-induced oxidative injury may be attributable to 
pathogenesis of infection with certain viruses that are 
resistant to the direct antiviral actions of NO, as observed 
with vaccinia virus.
The main hallmark of MDSCs is their tumor pro-
moting capacity. Various approaches have been tested 
to eliminate their presence, block their accumulation, 
minimize their immunosuppressive function and induce 
their differentiation into mature phenotype [42]. The 
accumulation of granulocytic MDSCs following onco-
lytic viral therapy in mice has been observed in many 
different tumor models [18, 32–34]. Furthermore, many 
viruses are not oncolytic but are still capable of creat-
ing an inflammatory environment and promoting the 
induction and accumulation of iNOS+ cells [43, 44]. We 
believe that there are no discrepancies between activated 
PMN-MDSC recruited in mice bearing xenograft tumors 
versus syngeneic tumors. A basic understanding of the 
role of these cells in response to VACV therapy in mice 
establishes a framework for future studies in clinical tri-
als. It is highly probable that inflammatory mediators 
generated during infection contribute to the recruitment 
of MDSCs. In previous studies other researchers and we 
have done profiling on mouse immune-related genes and 
showed a drastic change in the transcriptional increase 
in the pro-inflammatory genes. Among them, MCP-1 
(CCL-2), IL-1b, IL-6, TNF-α were especially shown to be 
involved in the recruitment of immature cells into tumor 
microenvironment [18, 45, 46].
Two recent observations about the function of MDSCs 
in virus-treated tumors highlight distinct and important 
aspects of these suppressors. In one of these studies, it 
has been shown that NK cell response to VACV infection 
is negatively regulated by granulocytic MDSCs [20]. In a 
more recent study, Eisenstein et al. exploring MDSCs as 
a vehicle to transport vesicular stomatitis virus (VSV), 
reported the differentiation of MDSCs towards M1-like 
phenotype following the encounter of MDSC with virus 
in tissue culture plate [17]. Our extensive in vivo analy-
sis not only parallel their findings, but also demonstrate 
that in  situ conversion of tumor-promoting MDSCs 
into tumor-killing cells by oncolytic VACV is an impor-
tant effector mechanism which directly contributes to 
the therapeutic effect of VACV. A combination of all of 
these results is particularly important because it indi-
cates the multiple immune modulatory effects of onco-
lytic vaccinia virotherapy through MDSCs. It is likely that 
iNOS+-MDSC can inhibit an antiviral immune response 
by blocking NK cells and suppressing CD8 T-cell activity 
during oncolysis. On the other hand, we cannot rule out 
the possibility that the accumulation of iNOS+-MDSC 
could also potentially hamper the subsequent develop-
ment of an antitumor T-cell response. We and other 
researchers have shown that NO production was respon-
sible for the suppression of T-cells [30–47]. However, our 
data indicated that the iNOS-upregulation is short-lived 
and possibly subsided by the time CTLs start infiltrating 
the tumors. Although we hypothesize that timing of CTL 
infiltration and iNOS-upregulation do not overlap, fur-
ther studies in syngeneic models are needed to delineate 
the exact kinetic.
The cells responsible for preventing the effective 
infection of the tumor following r.o. injection, appeared 
to be monocytic rather than neutrophilic cells. Different 
subsets of myeloid cells (monocytic and neutrophilic) 
have been reported during VACV infection [48]. In 
one of these studies, Ly6C+ phagocytic cells prevented 
spreading of virus and their depletion by Clodrosome 
enhanced the replication at the site of infection. Inter-
estingly, the lesion size was increased in the tissue of 
mice depleted of ly6G+ subsets. The response observed 
in our depletion and infection studies combined, did not 
differ from this finding. Clodronate liposome depletion 
was used as an alternative to antibody depletion target-
ing specifically the Ly6G+ component. However, Clo-
drosome did not deplete iNOS+ cells to the same extent 
as it is with the ly6G+ antibody but instead depleted 
exclusively F4/80+ monocytic cells. This caused a rapid 
and increased replication of VACV as it has been shown 
before [49].
Page 11 of 12Kilinc et al. J Transl Med  (2016) 14:340 
The heterogeneous composition of MDSCs under dif-
ferent conditions such as inflammatory/neoplastic in 
addition to the limited surface markers affected by dif-
ferent level of immaturity make comparison of different 
subsets with normal counterpart unlikely [50]. Therefore, 
we do not know whether the PMN-MDSC within the 
tumors are actually neutrophils or the immature precur-
sors of granulocytic MDSCs which include neutrophils 
at earlier stage of maturation and/or N1 versus N2 polar-
ized tumor-associated neutrophils (TAN) phenotypes. It 
is acknowledged that similar tumor cell cytotoxicity was 
observed with tumor-activated neutrophils during tumor 
progression. Interestingly, neutrophils can also acquire 
immunosuppressive activity if activated [51]. Although 
they were initially seen as cells with a sole function to 
eliminate invading microorganisms, growing evidence 
point out them as potent regulatory cells expressing 
numerous effector molecules. Taken together, there 
seems to be a significant functional overlap between 
PMN-MDSC and neutrophils in the cancer microenvi-
ronment and elevated iNOS activity is instrumental in 
both immunosuppression and tumoricidal activity, mak-
ing these two populations not only phenotypically but 
also functionally equivalent.
Conclusions
Clearly, a better understanding of the mechanisms of 
tumor regression by oncolytic viruses is needed to allow 
the induction of effective antitumor immunity result-
ing in a better therapeutic outcome. While implicated 
in few studies, a detailed understanding of how iNOS+ 
MDSCs modulate the antitumor immune response dur-
ing an oncolytic virus treatment remains under-explored. 
To the best of our knowledge, this is the first report that 
shows in vivo synergistic tumor cell killing by VACV and 
MDSCs. If this ability of MDSCs to switch from tumor-
promoting to tumor-killing could be effectively utilized, 
it may significantly enhance the therapeutic potential of 
oncolytic virus therapy.
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